 Merck & Co. tightened its outlook for the year as the effect of patent expirations again weighed on its sales in the third quarter. . The company’s earnings, however, declined less than expected.. Merck tightened its earnings outlook for the year by three cents on each end, to a range of $3.46 to $3.50 a share. It also lowered the top end...
  